CHiR Therapy for Elderly DLBCL Intolerant to Chemo
Recruiting now · Phase 2
Conditions studied: Diffuse Large B-Cell Lymphoma
In brief
The objective of exploring the application of CHiR is to evaluate its therapeutic efficacy and safety in newly diagnosed elderly patients with diffuse large B-cell lymphoma (DLBCL) aged 70 and above, and to investigate the genetic subtypes that may benefit from CHiR. The primary endpoint is the complete remission rate (CRR) at the end of 8 cycles.
Key facts
- Study ID
- NCT06764017
- Run by
- First Affiliated Hospital of Ningbo University
- People needed
- 30
- Starts
- 2025-02-01
- Expected to finish
- 2027-08-01
- Last updated by the study team
- 2025-03-19
Who can join
Age: 70 and older, up to 100. Sex: any. Healthy volunteers: not accepted.
Where it is running
- The First Affiliated Hospital of Ningbo University — Ningbo, Zhejiang, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.